SCHEMBL6509270

SCHEMBL6509270

CN(c1ccc2oc(C(=O)NO)cc2c1)S(=O)(=O)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT1 P54687 4/20 0.50
LMNA P02545 4/20 0.50
RAB9A P51151 2/20 0.50
NPC1 O15118 2/20 0.50
CLK1 P49759 1/20 0.50
MAPT P10636 3/20 0.49
THRB P10828 1/20 0.48
PTPN22 Q9Y2R2 6/20 0.48
ALDH1A1 P00352 3/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
HTT P42858 2/20 0.48
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
GAA P10253 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
MAPK1 P28482 1/20 0.47
PTPN1 P18031 1/20 0.46
PTPN12 Q05209 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6509960 0.93 PTPN22 (0.58) LMNARAB9ANPC1CLK1MAPT
SCHEMBL6510460 0.89 PTPN22 (0.50) BCAT1LMNARAB9ANPC1CLK1
SCHEMBL6509586 0.83 RAB9A (0.44) BCAT1LMNARAB9ANPC1CLK1
SCHEMBL6507327 0.75 ALDH1A1 (0.42) BCAT1LMNARAB9ANPC1CLK1
SCHEMBL6507296 0.75 HDAC1 (0.52) LMNAALDH1A1HDAC1HDAC8SMN1; SMN2
SCHEMBL15480600 0.74 GBA1 (0.64) LMNANPC1MAPTALDH1A1HDAC1
SCHEMBL6509267 0.72 BCAT1 (0.50) BCAT1LMNARAB9ANPC1CLK1
SCHEMBL6510159 0.71 HDAC6 (0.52) LMNARAB9ANPC1ALDH1A1HDAC1
SCHEMBL28891069 0.70 NPC1 (0.68) LMNARAB9ANPC1THRBALDH1A1
SCHEMBL13485789 0.70 NPC1 (0.68) LMNARAB9ANPC1THRBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005066151-A2 HISTONE DEACETYLASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2005-07-21 WO claimed
US-20050137234-A1 Histone deacetylase inhibitors SYRRX, INC. 2005-06-23 US claimed
WO-2005066151-A2 HISTONE DEACETYLASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2005-07-21 WO disclosed
WO-2005066151-A2 HISTONE DEACETYLASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2005-07-21 WO disclosed
US-20050137234-A1 Histone deacetylase inhibitors SYRRX, INC. 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137234-A1 Histone deacetylase inhibitors HDAC1, HDAC5, HDAC11 BCAT1 2085/4885LMNA 680/4885RAB9A 3382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.